The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis

Cancer Letters

Volumn 338, Issue 2, 2013, Pages 229-238

  Ren, Hui ^a,b   Zhao, Liqun ^b   Li, Yikun ^b   Yue, Ping ^b   Deng, Xingming ^b   Owonikoko, Taofeek K ^b   Chen, Mingwei ^a   Khuri, Fadlo R ^b   Sun, Shi Yong ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; BKM120; Lung cancer; PI3 kinase; TRAIL

Indexed keywords

BUPARLISIB; PROTEIN MCL 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG CANCER; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

APOPTOSIS; BKM120; LUNG CANCER; PI3 KINASE; TRAIL;

AMINOPYRIDINES; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; F-BOX PROTEINS; GLYCOGEN SYNTHASE KINASE 3; HCT116 CELLS; HUMANS; LUNG NEOPLASMS; MORPHOLINES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UBIQUITIN-PROTEIN LIGASES;

EID: 84881663741     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.03.032     Document Type: Article

References (46)

1. Maira S.M., Pecchi S., Huang A., Burger M., Knapp M., Sterker D., Schnell C., Guthy D., Nagel T., Wiesmann M., Brachmann S., Fritsch C., Dorsch M., Chene P., Shoemaker K., De Pover A., Menezes D., Martiny-Baron G., Fabbro D., Wilson C.J., Schlegel R., Hofmann F., Garcia-Echeverria C., Sellers W.R., Voliva C.F. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol. Cancer Ther. 2012, 11:317-328.
2. Zheng Y., Yang J., Qian J., Zhang L., Lu Y., Li H., Lin H., Lan Y., Liu Z., He J., Hong S., Thomas S., Shah J., Baladandayuthapani V., Kwak L.W., Yi Q. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J. Mol. Med. (Berl) 2011.
3. Koul D., Fu J., Shen R., LaFortune T.A., Wang S., Tiao N., Kim Y.W., Liu J.L., Ramnarian D., Yuan Y., Garcia-Echevrria C., Maira S.M., Yung W.K. Antitumor activity of NVP-BKM120 - a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin. Cancer Res. 2012, 18:184-195.
4. Bendell J.C., Rodon J., Burris H.A., de Jonge M., Verweij J., Birle D., Demanse D., De Buck S.S., Ru Q.C., Peters M., Goldbrunner M., Baselga J. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 2012, 30:282-290.
5. Kelley S.K., Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr. Opin. Pharmacol. 2004, 4:333-339.
6. Bellail A.C., Qi L., Mulligan P., Chhabra V., Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 2009, 4:34-41.
7. Ashkenazi A., Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 2008, 118:1979-1990.
8. Zhang L., Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene. Ther. 2005, 12:228-237.
9. Abdulghani J., El-Deiry W.S. TRAIL receptor signaling and therapeutics. Expert Opin. Ther. Targets 2010, 14:1091-1108.
10. Opel D., Westhoff M.A., Bender A., Braun V., Debatin K.M., Fulda S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res. 2008, 68:6271-6280.
11. Kim S., Kang J., Qiao J., Thomas R.P., Evers B.M., Chung D.H. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J. Pediatr. Surg. 2004, 39:516-521.
12. Larribere L., Khaled M., Tartare-Deckert S., Busca R., Luciano F., Bille K., Valony G., Eychene A., Auberger P., Ortonne J.P., Ballotti R., Bertolotto C. PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. Cell Death Differ. 2004, 11:1084-1091.
13. Rychahou P.G., Murillo C.A., Evers B.M. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand (TRAIL). Surgery 2005, 138:391-397.
14. Oka N., Tanimoto S., Taue R., Nakatsuji H., Kishimoto T., Izaki H., Fukumori T., Takahashi M., Nishitani M., Kanayama H.O. Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci. 2006, 97:1093-1098.
15. Opel D., Naumann I., Schneider M., Bertele D., Debatin K.M., Fulda S. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma. Clin. Cancer Res. 2011, 17:3233-3247.
16. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
17. Shirley S., Micheau O. Targeting c-FLIP in cancer. Cancer Lett. 2010.
18. Chan S.L., Yu V.C. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin. Exp. Pharmacol. Physiol. 2004, 31:119-128.
19. Sun S.Y., Yue P., Dawson M.I., Shroot B., Michel S., Lamph W.W., Heyman R.A., Teng M., Chandraratna R.A., Shudo K., Hong W.K., Lotan R. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res. 1997, 57:4931-4939.
20. Sun S.Y., Yue P., Zhou J.Y., Wang Y., Choi Kim H.R., Lotan R., Wu G.S. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells. Biochem. Biophys. Res. Commun. 2001, 280:788-797.
21. Lois C., Hong E.J., Pease S., Brown E.J., Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002, 295:868-872.
22. Liu X., Yue P., Zhou Z., Khuri F.R., Sun S.Y. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J. Natl. Cancer Inst. 2004, 96:1769-1780.
23. Sun S.Y., Yue P., Wu G.S., El-Deiry W.S., Shroot B., Hong W.K., Lotan R. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999, 18:2357-2365.
24. Mao J.H., Perez-Losada J., Wu D., Delrosario R., Tsunematsu R., Nakayama K.I., Brown K., Bryson S., Balmain A. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 2004, 432:775-779.
25. Wang X., Chen W., Zeng W., Bai L., Tesfaigzi Y., Belinsky S.A., Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol. Cancer Ther. 2008, 7:1156-1163.
26. Jacquemin G., Granci V., Gallouet A.S., Lalaoui N., Morle A., Iessi E., Morizot A., Garrido C., Guillaudeux T., Micheau O. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica 2012, 97:38-46.
27. Ricci M.S., Kim S.H., Ogi K., Plastaras J.P., Ling J., Wang W., Jin Z., Liu Y.Y., Dicker D.T., Chiao P.J., Flaherty K.T., Smith C.D., El-Deiry W.S. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer cell 2007, 12:66-80.
28. Son J.K., Varadarajan S., Bratton S.B. TRAIL-activated stress kinases suppress apoptosis through transcriptional upregulation of MCL-1. Cell Death Differ. 2010, 17:1288-1301.
29. Inuzuka H., Shaik S., Onoyama I., Gao D., Tseng A., Maser R.S., Zhai B., Wan L., Gutierrez A., Lau A.W., Xiao Y., Christie A.L., Aster J., Settleman J., Gygi S.P., Kung A.L., Look T., Nakayama K.I., DePinho R.A., Wei W. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011, 471:104-109.
30. Wertz I.E., Kusam S., Lam C., Okamoto T., Sandoval W., Anderson D.J., Helgason E., Ernst J.A., Eby M., Liu J., Belmont L.D., Kaminker J.S., O'Rourke K.M., Pujara K., Kohli P.B., Johnson A.R., Chiu M.L., Lill J.R., Jackson P.K., Fairbrother W.J., Seshagiri S., Ludlam M.J., Leong K.G., Dueber E.C., Maecker H., Huang D.C., Dixit V.M. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471:110-114.
31. Kanei-Ishii C., Nomura T., Takagi T., Watanabe N., Nakayama K.I., Ishii S. Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation. J. Biol. Chem. 2008, 283:30540-30548.
32. Gregory M.A., Qi Y., Hann S.R. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J. Biol. Chem. 2003, 278:51606-51612.
33. Welcker M., Orian A., Jin J., Grim J.E., Harper J.W., Eisenman R.N., Clurman B.E. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. USA 2004, 101:9085-9090.
34. Bagci-Onder T., Wakimoto H., Anderegg M., Cameron C., Shah K. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res. 2011, 71:154-163.
35. Viswanath V., Wu Y., Boonplueang R., Chen S., Stevenson F.F., Yantiri F., Yang L., Beal M.F., Andersen J.K. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J. Neurosci. 2001, 21:9519-9528.
36. Ferreira K.S., Kreutz C., Macnelly S., Neubert K., Haber A., Bogyo M., Timmer J., Borner C. Caspase-3 feeds back on caspase-8, Bid and XIAP in type I Fas signaling in primary mouse hepatocytes. Apoptosis 2012, 17:503-515.
37. Huang S., Sinicrope F.A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 2008, 68:2944-2951.
38. Huang S., Okumura K., Sinicrope F.A. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin. Cancer Res. 2009, 15:150-159.
39. Mott J.L., Bronk S.F., Mesa R.A., Kaufmann S.H., Gores G.J. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol. Cancer Ther. 2008, 7:2339-2347.
40. Yeow W.S., Baras A., Chua A., Nguyen D.M., Sehgal S.S., Schrump D.S. Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Thorac. Cardiovasc. Surg. 2006, 132:1356-1362.
41. Ray S., Bucur O., Almasan A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis 2005, 10:1411-1418.
42. Elrod H.A., Sun S.Y. Modulation of death receptors by cancer therapeutic agents. Cancer Biol. Ther. 2007, 7:163-173.
43. Sun S.Y. Chemopreventive agent-induced modulation of death receptors. Apoptosis 2005, 10:1203-1210.
44. Thomas L.W., Lam C., Edwards S.W. Mcl-1; the molecular regulation of protein function. FEBS Lett. 2010, 584:2981-2989.
45. Chan G., Nogalski M.T., Bentz G.L., Smith M.S., Parmater A., Yurochko A.D. PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes. J. Immunol. 2010, 184:3213-3222.
46. Brachmann S.M., Kleylein-Sohn J., Gaulis S., Kauffmann A., Blommers M.J., Kazic-Legueux M., Laborde L., Hattenberger M., Stauffer F., Vaxelaire J., Romanet V., Henry C., Murakami M., Guthy D.A., Sterker D., Bergling S., Wilson C., Brummendorf T., Fritsch C., Garcia-Echeverria C., Sellers W.R., Hofmann F., Maira S.M. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol. Cancer Ther. 2012, 11:1747-1757.